The ANXA7 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population of human embryonic kidney HEK293T cells, designed for loss-of-function studies of ANXA7. The product represents a heterogeneous pool of cells with targeted disruption of the ANXA7 gene through CRISPR/Cas9-mediated gene editing, without clonal isolation. This format provides a cost-effective and robust model for functional genomics, enabling researchers to investigate ANXA7-dependent phenotypes in a relevant cellular background.
HEK293T cells are derived from human embryonic kidney cells transformed with adenovirus 5 DNA and expressing the SV40 large T antigen. These cells are widely utilized for transient protein expression and gene editing applications due to their high transfection efficiency and adaptability. The HEK293T line supports rapid proliferation and is a standard host for studying signaling pathways, including those mediated by EGFR and calcium signaling, making it a suitable context for examining ANXA7 function.
ANXA7 encodes a calcium-dependent phospholipid-binding protein that participates in membrane trafficking, exocytosis, and apoptosis. Mechanistically, ANXA7 is activated by calcium ions and regulated upstream by EGF/EGFR signaling and protein kinase C (PKC). It interacts with several key factors, including Bcl2, sorcin, and ALG-2 (PDCD6). Downstream, ANXA7 influences cytochrome c release and cell proliferation, acting as a node linking EGFR and calcium signaling to apoptotic cascades. In HEK293T cells, ANXA7 knockout disrupts these calcium-dependent processes, leading to altered cell survival.
In the context of HEK293T cells, loss of ANXA7 function provides a unique system to dissect its role in EGFR-mediated signaling and apoptosis. The polyclonal knockout population allows for the study of mixed genotypes, which may better reflect heterogeneous cellular responses compared to clonal lines. This model is particularly relevant for cancer biology research, given ANXA7’s implication in breast cancer, prostate cancer, and glioblastoma, as well as in neurological disorders like epilepsy. By using these cells, investigators can explore how ANXA7 governs membrane dynamics and cell fate decisions.
These polyclonal knockout cells are suitable for a broad array of experimental workflows. Researchers can perform western blotting and RT-qPCR to confirm ANXA7 disruption and downstream target expression, immunofluorescence and co-immunoprecipitation to study protein interactions, and calcium imaging and apoptosis assays to assess functional consequences. The cells are ideal for screening ANXA7-interacting proteins and for investigating EGFR signaling pathway integrity. Cell proliferation assays can be employed to evaluate the impact on growth. For further information or technical inquiries, please contact Ascent Research.
